💊 दवाएँ A-Z 🧬 लक्ष्य 🛠 उपकरण 📚 मार्गदर्शिकाएँ
सभी दवाएँ दवा वर्ग चिकित्सीय क्षेत्र दुष्प्रभाव
मार्गदर्शिकाएँ शब्दकोश समयरेखा
तुलनाएँ दवाओं की यात्राएँ दवा परिवार
🇺🇸 English 🇰🇷 한국어 🇯🇵 日本語 🇨🇳 中文简体 🇪🇸 Español 🇧🇷 Português 🇮🇳 हिन्दी 🇸🇦 العربية 🇫🇷 Français 🇷🇺 Русский 🇩🇪 Deutsch 🇹🇷 Türkçe 🇻🇳 Tiếng Việt 🇮🇩 Bahasa Indonesia 🇹🇭 ไทย

Ferumoxytol

CHEMBL1201867 Phase 4 अनुमोदित Unknown
Half-Life
—
Bioavailability
—
Protein Binding
—
Molecular Weight
231.5 g/mol
LogP
—
Phase
4

This injectable iron oxide nanoparticle preparation is used to treat iron deficiency anemia in adults with chronic kidney disease or other conditions who cannot tolerate or absorb oral iron. It can also serve as an MRI contrast agent due to its magnetic properties.

आणविक भार

231.5300 g/mol

TPSA

4.00 Ų

चिकित्सीय क्षेत्र

Ovarian Cancer Pancreatic Cancer Bladder Cancer Thyroid Cancer Non-Small Cell Lung Cancer Epilepsy Migraine Multiple Sclerosis Chronic Kidney Disease Stroke Deep Vein Thrombosis / Pulmonary Embolism Obesity Lymphoma Type 2 Diabetes Breast Cancer Heart Failure Cardiovascular Disease Prostate Cancer Colorectal Cancer Leukemia

क्रिया का तंत्र

Enhances the contrast of specific tissues or structures during medical imaging procedures by altering the local signal intensity or X-ray absorption characteristics.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

तंत्र

Enhances the contrast of specific tissues or structures during medical imaging procedures by altering the local signal intensity or X-ray absorption characteristics.

2D संरचना

SVG PNG

Cite this structure


                        

                            
                            
                        

                    

                


                
                

                    

                    

                        
Embed this structure

                        

                        

                            
                            
                        

                    

                

                

                
                

                    
SMILES

                    
[O-2].[O-2].[O-2].[O-2].[Fe+2].[Fe+3].[Fe+3]

                

                

                
                

                    
InChI

                    
InChI=1S/3Fe.4O/q+2;2*+3;4*-2

                

                

                

                    
                    

                        
Molecular Formula

                        
Fe3O4

                    

                    
                    

                        
HBD / HBA

                        
- / 4

                    

                    
                    

                        
घूर्णनीय बंधन

                        
0

                    

                    
                    
                    

                        
भारी परमाणु

                        
7

                    

                    
                

            


            
            

                
                


    
    
        
    
    
    
No targets recorded

    
    
Target interaction data is not yet available for this drug.

    



                
            


            
            

                
                


    
    
        
    
    
    
No interactions recorded

    
    
Drug interaction data is not yet available for this compound.

    



                
            


            
            

                
                


    
    
        
    
    
    
No side effects recorded

    
    
Side effect data is not yet available for this drug.

    



                
            


            
            
            

                
अक्सर पूछे जाने वाले प्रश्न

                

                    
                    

                        
                        

                            
This injectable iron oxide nanoparticle preparation is used to treat iron deficiency anemia in adults with chronic kidney disease or other conditions who cannot tolerate or absorb oral iron. It can also serve as an MRI contrast agent due to its magnetic properties.

                        

                    

                    

                    

                    
                    

                        
                        

                            
Enhances the contrast of specific tissues or structures during medical imaging procedures by altering the local signal intensity or X-ray absorption characteristics.

                        

                    

                    

                    

                    

                        
                        

                            
Yes, Ferumoxytol is an approved drug. It has reached clinical phase 4. It is classified as a Unknown.

                        

                    

                

            

            

            
            

            
            

            
            
{# References & Data Sources section for drug detail pages.
   Renders standard pharmacological database links plus the drug's data_sources field. #}


    
References & Data Sources

    
    
        
        
  • 
            
            
                ChEMBL — European Bioinformatics Institute (EBI).
                CHEMBL1201867.
                Open-access bioactivity database.
            
        
    • 
        
        
        
  • 
            
            
                PubChem — National Center for Biotechnology Information (NCBI).
                CID 6432052.
                Chemical information database.
            
        
    • 
        
        
        
        
    

    
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.




        


        
        
    


    



    
चिकित्सा अस्वीकरण

    

        This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.
    

    

        Data sources:
        ChEMBL,
        PubChem,
        DailyMed.